129 related articles for article (PubMed ID: 31711243)
21. Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer.
Giovanella L; Castellani M; Suriano S; Ruberto T; Ceriani L; Tagliabue L; Lucignani G
Tumori; 2011; 97(5):629-33. PubMed ID: 22158495
[TBL] [Abstract][Full Text] [Related]
22. Protocol-driven multidetector SPECT/CT: integration of hybrid imaging into the routine workflow of whole-body bone scintigraphy in oncology patients.
Adusumilli P; Nejadhamzeeigilani H; Pitts K; McDermott G; Scarsbrook AF; Vaidyanathan S; Patel CN; Chowdhury FU
Clin Radiol; 2020 Jan; 75(1):79.e1-79.e7. PubMed ID: 31601386
[TBL] [Abstract][Full Text] [Related]
23. Whole-body bone SPECT in breast cancer patients: the future bone scan protocol?
Abikhzer G; Gourevich K; Kagna O; Israel O; Frenkel A; Keidar Z
Nucl Med Commun; 2016 Mar; 37(3):247-53. PubMed ID: 26528786
[TBL] [Abstract][Full Text] [Related]
24. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
25. Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup.
Rager O; Nkoulou R; Exquis N; Garibotto V; Tabouret-Viaud C; Zaidi H; Amzalag G; Lee-Felker SA; Zilli T; Ratib O
Biomed Res Int; 2017; 2017():7039406. PubMed ID: 28812019
[TBL] [Abstract][Full Text] [Related]
26. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of SPECT-CT on bone scintigraphy in oncology: Pattern approach.
Tuncel M; Lay Ergun E; Caglar Tuncali M
J BUON; 2016; 21(5):1296-1306. PubMed ID: 27837636
[TBL] [Abstract][Full Text] [Related]
28. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S
Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323
[TBL] [Abstract][Full Text] [Related]
29. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
30. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
31. The improved accuracy of planar bone scintigraphy by adding single photon emission computed tomography (SPECT-CT) to detect skeletal metastases from prostate cancer.
McLoughlin LC; O'Kelly F; O'Brien C; Sheikh M; Feeney J; Torreggiani W; Thornhill JA
Ir J Med Sci; 2016 Feb; 185(1):101-5. PubMed ID: 25394725
[TBL] [Abstract][Full Text] [Related]
32. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.
Tabotta F; Jreige M; Schaefer N; Becce F; Prior JO; Nicod Lalonde M
BMC Musculoskelet Disord; 2019 Dec; 20(1):619. PubMed ID: 31878904
[TBL] [Abstract][Full Text] [Related]
33. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer.
Haraldsen A; Bluhme H; Røhl L; Pedersen EM; Jensen AB; Hansen EB; Nellemann H; Rasmussen F; Morsing A
Clin Physiol Funct Imaging; 2016 Jan; 36(1):40-6. PubMed ID: 25257661
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
35. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate.
Helyar V; Mohan HK; Barwick T; Livieratos L; Gnanasegaran G; Clarke SE; Fogelman I
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):706-13. PubMed ID: 20016889
[TBL] [Abstract][Full Text] [Related]
36. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
37. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
38. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
Schmidkonz C; Götz TI; Atzinger A; Ritt P; Prante O; Kuwert T; Bäuerle T; Goebell P; Cordes M
Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
[TBL] [Abstract][Full Text] [Related]
39. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
